Higher risk due to health condition

People living with HIV show normal antibody longevity after full COVID-19 vaccination and have strong third dose responses

In a paper now published in the Journal of Infectious Diseases, Drs. Zabrina Brumme and Mark Brockman from Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and members of the Canadian HIV Trials Network, led by Dr. Aslam Anis from the University of British Columbia, demonstrate that responses to COVID-19 vaccines in people living with HIV (PLWH) are similar to those without HIV.

2022-06-20T10:07:10-04:00June 17, 2022|Higher risk due to health condition|

Third doses lead to high antibody responses among people living with inflammatory bowel disease (IBD)

Over 99% of a subset of individuals living with inflammatory bowel disease (IBD) mounted an antibody response against the spike protein after their third vaccine dose, found a letter published in Gut, under the leadership of Dr. Gil Kaplan (University of Calgary) and co-authored by Dr. Sasha Bernatsky (Research Institute of the McGill University Health Centre), who are funded by CITF.

2022-06-06T09:50:19-04:00June 6, 2022|Higher risk due to health condition|

Vaccination in individuals living with immune-mediated inflammatory diseases is highly effective against SARS-CoV-2 infection and severe outcomes

New findings from the CITF-funded SUCCEED project, published in The Lancet Rheumatology, indicate that two doses of mRNA vaccines were 79 to 89% effective at preventing SARS-CoV-2 infection in individuals living with immune-mediated inflammatory diseases in Ontario.

People with HIV show normal antibody longevity after dual COVID-19 vaccination, and strong third dose responses

In a pre-print, not yet peer reviewed, Drs. Zabrina Brumme and Mark Brockman from Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and members of the Canadian HIV Trials Network, led by Dr. Aslam Anis from the University of British Columbia, demonstrated that responses to COVID-19 vaccines in people living with HIV (PLWH) are similar to those in controls without HIV.

2022-04-18T09:02:35-04:00March 25, 2022|Higher risk due to health condition|

Uptake of third vaccine doses in people with inflammatory bowel disease

In this short correspondence published in The Lancet Gastroenterology and Hepatology, CITF-funded researchers Dr. Jessica Widdifield of the University of Toronto, Dr. Sasha Bernatsky of McGill University, and colleagues presented the frequency of SARS-CoV-2 vaccination in Ontario patients with inflammatory bowel disease (IBD).

2022-04-18T09:02:41-04:00March 8, 2022|Higher risk due to health condition|

Antibody responses to two-dose COVID-19 vaccination in people living with HIV

In a research study originally released as a preprint, and now published in npj vaccines, Drs. Zabrina Brumme and Mark Brockman, from the BC Centre for Excellence in HIV/AIDS and Simon Fraser University, evaluated antibody responses to COVID-19 vaccines in people living with HIV who were receiving suppressive antiretroviral therapy.

2022-04-18T09:02:44-04:00March 1, 2022|Higher risk due to health condition|
Go to Top